Filing Flows › Citius Oncology (CTOR) › Q2 FY26
Citius Oncology (CTOR) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed May 15, 2026
Citius Oncology (CTOR) reported revenue of $1.7M for the second quarter fiscal 2026 (Q2 FY26) and -58% from the quarter before.
Citius Oncology, Q2 FY26: revenue $1.7M, net loss $26.6M, operating cash flow −$3.8M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | -58% | — |
| Operating profit | −$28.6M | — | — |
| Net earnings | −$26.6M | — | — |
| Operating cash flow | −$3.8M | — | — |
What changed
Revenue was $1.7M in Q2 FY26, down 58% from the previous quarter.
Gross margin was 80.3%. Operating costs exceeded revenue by $28.6M, an operating margin of -1716.2%. The quarter ended with a net loss of $26.6M, wider than the previous quarter's $5.5M loss.
Operating cash flow was −$3.8M. Non-cash charges added back $3.5M of share-based compensation. Working capital and other items added $19.3M.
Questions
What was Citius Oncology's revenue in the second quarter fiscal 2026?
Citius Oncology (CTOR) reported revenue of $1.7M for the second quarter fiscal 2026 (Q2 FY26) and -58% from the quarter before.
Source: Citius Oncology 10-Q on SEC EDGAR.